Quality assessment of glycopeptide susceptibility tests: A european collaborative study

International Journal of Antimicrobial Agents

Volumn 9, Issue 3, 1998, Pages 153-163

  Brown, Derek F J ^a   Courvalin, Patrice ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b World Health Organisation Collaborating Center for Foodborne Listeriosis   (France)

Author keywords

Glycopeptides; Quality assurance; Susceptibility testing; Teicoplanin; Vancomycin

Indexed keywords

GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HUMAN; LABORATORY; LABORATORY TEST; LACTOBACILLUS; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SCREENING; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; EUROPE; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; TEICOPLANIN; VANCOMYCIN;

EID: 0031929548     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(97)00047-2     Document Type: Article

References (42)

1. Woodford N., Johnson A.P., Morrison D., Speller D.C.E. Current perspectives on glycopeptide resistance. Clin Microbiol Rev. 8:1995;585-615.
2. Arthur M., Reynolds P., Courvalin P. Glycopeptide resistance in enterococci. Trends Microbiol. 4:1996;401-407.
3. Report. Nosocomial enterococci resistant to vancomycin. MMWR 1993;42:597-599.
4. Report. Vancomycin resistant enterococci in hospitals in the United Kingdom. CDR Weekly 1995;5:281-284.
5. Kaatz G.W., Seo S.M., Lamp K.C., Bailey E.M., Rybak M.J. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis. 162:1994;103-108.
6. Vedel G., Leruez M., Lémaan F., Hraoui E., Ratovohery D. Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs. Eur J Clin Microbiol. 9:1990;820-822.
7. Brunet F.G., Vedel F., Dreyfus J.et al. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J Clin Microbiol. 9:1994;145-147.
8. Mainardi J.-L., Shlaes D.M., Goering R.V.et al. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis. 171:1995;1646-1650.
9. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
10. Grant A.C., Lacey R.W., Brownjohn A.M., Turney J.H. Teicoplanin-resistant coagulase-negative staphylococcus. Lancet. ii:1986;1166-1167.
11. Schwalbe R.S., Stapleton J.T., Gilligan P.H. Emergence of vancomycin resistance in coagulase-negative staphylococci. New Engl J Med. 316:1987;927-931.
12. Aubert G., Passot S., Lucht F., Dorche G. Selection of vancomycin- and teicoplanin-resistant Staphylococcus haemolyticus during teicoplanin treatment of Staphylococcus epidermidis infection. J Antimicrob Chemother. 25:1990;491-493.
13. Hunter P.R., George R.C., Griffiths J.W. Mathematical modeling of antimicrobial susceptibility data of Staphylococcus haemolyticus for 11 antimicrobial agents, including three experimental glycopeptides and an experimental lipoglycopeptide. Antimicrob Agents Chemother. 34:1990;1769-1772.
14. Maugein J., Pellegrin J.L., Brossard G., Fourche J., Leng B., Reiffers J. In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients. Antimicrob Agents Chemother. 34:1990;901-903.
15. Veach L.A., Pfaller M.A., Barrett M., Koontz F.P., Wenzel R.P. Vancomycin resistance in Staphylococcus haemolyticus causing colonisation and bloodstream infection. J Clin Microbiol. 28:1990;2064-2068.
16. Chomarat M., Espinouse D., Flandrois J.-P. Coagulase-negative staphylococci emerging during teicoplanin therapy and problems in the determination of their sensitivity. J Antimicrob Chemother. 27:1991;475-480.
17. Bourgeois F., Bingen E., Lambert-Zechovsky N. Comparative in vitro activity of glycopeptides against coagulase-negative staphylococci isolated in pediatric hospital units. Pathol Biol. 40:1992;36-39.
18. Desroys Du Roure F., Herrmann J.L., Lagrange P.H., Bouvet A. Action of teicoplanin on coagulase negative staphylococci in hospital units of the hospital Hotel-Dieu in Paris. Pathol Biol. 41:1993;302-306.
19. Jean-Pierre H., Riviere M., Darbas H., Boyer G. In vitro activity of glycopeptides on 114 coagulase-negative staphylococci: Problems with the teicoplanin disk diffusion test, 'alert' parameters indicating a need for MIC determination. Pathol Biol. 41:1993;531-536.
20. Sanyal D., Johnson A.P., George R.C., Edwards R., Greenwood D. In-vitro characteristics of glycopeptide resistant strains of Staphylococcus epidermidis isolated from patients on CAPD. J Antimicrob Chemother. 32:1993;267-278.
21. Cercenado E., Garcia-Leoni M.E., Diaz M.D., Sánchez-Carillo C., Catalan P., Bernaldo de Quirós J.C.L., Bouza E. Emergence of teicoplanin-resistant coagulase-negative staphylococci. J Clin Microbiol. 34:1996;1765-1768.
22. Weiss K., Rouleau D., Laverdière M. Cystitis due to vancomycin-intermediate Staphylococcus saprophyticus. J Antimicrob Chemother. 37:1996;1039-1040.
23. Sahm D.F., Olsen L. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother. 33:1989;1588-1591.
24. Sahm D.F., Kissinger J., Gilmore M.S. In vitro detection of enterococcal vancomycin resistance. Antimicrob Agents Chemother. 34:1990;1846-1848.
25. Willey B.M., Kreiswirth B.M., Simor A.E.et al. Detection of vancomycin resistance in Enterococcus species. J Clin Microbiol. 30:1992;1621-1624.
26. Tenover F.C., Tokars J., Swenson J., Paul S., Spitalny K., Jarvis W. Ability of clinical laboratories to detect antimicrobial agent-resistant enterococci. J Clin Microbiol. 31:1993;1695-1699.
27. Zabransky R.J., DiNuzo A.R., Huber M.B., Woods G.L. Detection of vancomycin resistance in enterococci by the Vitek AMS system. Diagn Microbiol Infect Dis. 20:1994;113-116.
28. Tenover F.C., Swenson J.M., O'Hara C.M., Stocker S.A. Ability of commercial and reference antimicrobial susceptibility testing methods to detect vancomycin resistance in enterococci. J Clin Microbiol. 33:1995;1524-1527.
29. Snell J.J.S., Brown D.F.J., Perry S.F., George R. Antimicrobial susceptibility testing of enterococci: Results of a survey conducted by the United Kingdom National External Quality Assessment Scheme for Microbiology. J Antimicrob Chemother. 32:1993;401-412.
30. Kenny M.T., Mayer G.D., Dulworth J.K., Brackman M.A., Farrer K. Evaluation of the teicoplanin broth microdilution and disk diffusion susceptibility tests and recommended interpretive criteria. Diagn Microbiol Infect Dis. 15:1992;609-612.
31. Felmingham D., Solomonides K., O'Hare M.D., Wilson A.P.R., Grüneberg R.N. The effect of medium and inoculum on the activity of vancomycin and teicoplanin against coagulase-negative staphylococci. J Antimicrob Chemother. 20:1987;609-610.
32. Jones RN. Antimicrobial activity of teicoplanin: A review of in vitro activity, including susceptibility testing guidelines and a critical evaluation of potency against Staphylococcus haemolyticus. In: Phillips I, editor. Focus on Coagulase-negative Staphylococci. London: Royal Society of Medicine Services, 1989.
33. Jensen K.T., Schønheyder H., Gottschau, Thomsen V.F. Impact of agar medium and disc type on disc diffusion susceptibility testing against teicoplanin and vancomycin. Acta Pathol Microbiol Immunol Scand. 102:1994;94-102.
34. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, second ed. Approved Standard M7-A3. Villanova, PA: National Committee for Clinical Laboratory Standards, 1993.
35. National Committee for Clinical Laboratory Standards. Performance testing for antimicrobial susceptibility testing. Fifth informational supplement M100S5. Villanova, PA: National Committee for Clinical Laboratory Standards, 1994.
36. Low D.E., McGeer A., Poon R. Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococus epidermidis, including evaluation of susceptibility testing recommendations. Antimicrob Agents Chemother. 33:1989;585-588.
37. Martin E., Nouvellon M., Pestel M., Pons J.L., Leleland J.F. Evaluation of the Epsilometer test (E test) for testing the susceptibility of coagulase-negative staphylococci to teicoplanin. J Antimicrob Chemother. 36:1995;83-91.
38. The National Committee for Clinical Laboratory Standards Working Group on Enterococci, Swenson J.M., Ferraro M.J., Sahm D.F., Charache P. New vancomycin disk diffusion breakpoints for enterococci. J Clin Microbiol. 30:1992;2525-2528.
39. Swenson J.M., Clark N.C., Ferraro M.J.et al. Development of a standardized screening method for detection of vancomycin-resistant enterococci. J Clin Microbiol. 32:1994;1700-1704.
40. Schulz J.E., Sahm D.F. Reliability of the E test for detection of ampicillin, vancomycin and high-level aminoglycoside resistance in Enterococcus spp. J Clin Microbiol. 31:1993;3336-3339.
41. Poyart C, Pierre C, Quesne G, Pron B, Berche P, Trieu-Cuot P. Emergence of vancomycin resistance in the genus Streptococcus. Characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob Agents Chemother 1997;41:24-29.
42. Leclercq R., Derlot E., Weber M., Duval J., Courvalin P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 33:1989;10-15.